• Hereditary angioedema

Cinryze Generic Name & Formulations

General Description

C1 esterase inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.

Pharmacological Class

C1 inhibitor.

How Supplied

Single-use vial—1

Generic Availability


Cinryze Indications


Routine prophylaxis against angioedema attacks in patients ≥6yrs with hereditary angioedema (HAE).

Cinryze Dosage and Administration


Give by IV infusion at a rate of 1mL/min (10mins). ≥12yrs: 1000 Units every 3–4 days. May consider doses up to 2500 Units (max 100 Units/kg) every 3–4 days if inadequate response.


<6yrs: not established. Give by IV infusion at a rate of 1mL/min (5mins). 6–11yrs: 500 Units every 3–4 days. May adjust dose up to 1000 Units every 3–4 days based on response.

Cinryze Contraindications

Not Applicable

Cinryze Boxed Warnings

Not Applicable

Cinryze Warnings/Precautions


Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Pregnancy. Nursing mothers.

Cinryze Pharmacokinetics

See Literature

Cinryze Interactions

Cinryze Adverse Reactions

Adverse Reactions

Headache, nausea, rash, vomiting, fever; thrombotic events, hypersensitivity reactions (may be severe; discontinue if occur).

Cinryze Clinical Trials

See Literature

Cinryze Note


To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.

Cinryze Patient Counseling

See Literature